A study on the safety and immune response of AS37 together with Hepatitis B antigen in adults aged 18-45 years

Trial Identifier: 215301
Sponsor: GlaxoSmithKline
Start Date: October 2022
Primary Completion Date: November 2024
Study Completion Date: November 2024
Condition: Hepatitis B

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
BELGIUM Leuven, BELGIUM, 3000
GERMANY Koeln, GERMANY, 51069
GERMANY Magdeburg, GERMANY, 39120
GERMANY, Hamburg Hamburg, GERMANY, 22143
UNITED_KINGDOM Cambridge, UNITED_KINGDOM, CB2 2GG